{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Amendments-and-Notifications”
},
“headline”: “SOP for Ethics Committee and IRB Amendments and Notifications”,
“description”: “This SOP defines standardized procedures for submitting amendments and notifications to Ethics Committees and IRBs, ensuring compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 25/12/2025
Standard Operating Procedure for EC/IRB Amendments and Notifications
| Department | Clinical Research |
| SOP No. | CR/ETH/008/2025 |
| Supersedes | NA |
| Page No. | 1 of 20 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to provide guidance on the preparation, submission, and follow-up of amendments and notifications to Ethics Committees (EC) and Institutional Review Boards (IRB). It ensures compliance with international
Scope
This SOP applies to sponsors, investigators, regulatory affairs staff, and quality assurance teams engaged in submitting protocol amendments, administrative changes, and safety-related notifications to EC/IRBs for clinical trials.
Responsibilities
- Principal Investigator (PI): Initiates protocol amendments and notifies EC/IRB of site-level changes.
- Regulatory Affairs Manager: Compiles and submits amendment packages and notifications to EC/IRBs.
- Clinical Research Associate (CRA): Ensures sites implement approved changes and maintains amendment records.
- Quality Assurance Officer: Reviews amendment documents for compliance before submission.
- Head of Clinical Research: Provides final approval before amendment submission.
Accountability
The Regulatory Affairs Head is accountable for ensuring that amendments and notifications are submitted promptly, accurately, and in accordance with regulatory requirements. Non-compliance may result in trial delays, ethical non-conformance, or regulatory findings.
Procedure
1. Identification of Amendment or Notification Requirement
Determine whether change qualifies as substantial (requiring EC/IRB approval) or non-substantial (requiring notification only).
Document reason for amendment or notification in Amendment Request Form.
2. Preparation of Amendment/Notification Package
Update trial documents such as protocol, informed consent forms, or recruitment materials.
Include cover letter, amendment description, justification, and impact analysis.
Compile supporting data (safety reports, investigator’s brochure updates, etc.).
3. Internal Review
QA verifies accuracy, completeness, and compliance with guidelines.
Head of Clinical Research approves final package.
4. Submission to EC/IRB
Submit amendment/notification electronically or in hard copy as per EC/IRB requirements.
Obtain acknowledgment of receipt.
Record submission details in Communication Log.
5. Follow-up and Approval Tracking
Track review and approval timelines in Amendment Tracker.
Respond promptly to EC/IRB queries.
File final approval letters in Trial Master File (TMF).
6. Implementation
Ensure approved changes are implemented at sites.
Provide training for site staff if amendments affect trial conduct.
Abbreviations
- SOP: Standard Operating Procedure
- EC: Ethics Committee
- IRB: Institutional Review Board
- PI: Principal Investigator
- CRA: Clinical Research Associate
- QA: Quality Assurance
- TMF: Trial Master File
Documents
- Amendment Request Form (Annexure-1)
- Amendment Tracker (Annexure-2)
- EC/IRB Communication Log (Annexure-3)
References
- ICH E6(R2) Good Clinical Practice
- US FDA 21 CFR Part 56 – IRB Requirements
- EMA Clinical Trial Regulation (EU No. 536/2014)
- WHO Guidelines for Ethics Committees
- CDSCO Clinical Trial Rules, India (2019)
Version: 1.0
Approval Section
| Prepared By | Rajesh Kumar, Regulatory Affairs Specialist |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head of Clinical Research |
Annexures
Annexure-1: Amendment Request Form
| Date | Protocol No. | Description | Reason | Initiated By |
|---|---|---|---|---|
| 01/09/2025 | CTP-2025-02 | Change in visit schedule | Operational feasibility | Dr. Meera Joshi |
Annexure-2: Amendment Tracker
| Amendment No. | Date Submitted | EC/IRB | Status | Remarks |
|---|---|---|---|---|
| 01 | 05/09/2025 | Metro EC | Approved | Conditions: update ICF |
Annexure-3: EC/IRB Communication Log
| Date | EC/IRB | Query | Response | Responsible Person |
|---|---|---|---|---|
| 12/09/2025 | Metro EC | Clarify recruitment materials | Submitted revised flyer | Rajesh Kumar |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Research |
For more SOPs visit: Pharma SOP